Moore Capital Management LP Has $15.30 Million Holdings in Revolution Medicines, Inc. $RVMD

Moore Capital Management LP increased its position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 46.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 81,700 shares of the company’s stock after purchasing an additional 26,100 shares during the period. Moore Capital Management LP’s holdings in Revolution Medicines were worth $15,301,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Meeder Advisory Services Inc. lifted its position in Revolution Medicines by 3.0% in the first quarter. Meeder Advisory Services Inc. now owns 4,126 shares of the company’s stock worth $401,000 after purchasing an additional 120 shares during the period. PNC Financial Services Group Inc. increased its stake in Revolution Medicines by 1.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 10,066 shares of the company’s stock valued at $802,000 after acquiring an additional 125 shares during the period. Northwestern Mutual Wealth Management Co. raised its position in Revolution Medicines by 147.7% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 218 shares of the company’s stock worth $41,000 after purchasing an additional 130 shares in the last quarter. Deutsche Bank AG lifted its stake in Revolution Medicines by 0.4% during the fourth quarter. Deutsche Bank AG now owns 32,217 shares of the company’s stock worth $2,566,000 after purchasing an additional 130 shares during the period. Finally, Contravisory Investment Management Inc. bought a new position in Revolution Medicines during the second quarter worth about $32,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Stephen Michael Kelsey sold 4,175 shares of the stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $156.12, for a total value of $651,801.00. Following the sale, the insider directly owned 291,876 shares in the company, valued at $45,567,681.12. This trade represents a 1.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Sushil Patel sold 5,580 shares of Revolution Medicines stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $187.99, for a total transaction of $1,048,984.20. Following the transaction, the director directly owned 21,656 shares in the company, valued at $4,071,111.44. The trade was a 20.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 212,497 shares of company stock worth $38,206,486 over the last quarter. Insiders own 7.60% of the company’s stock.

Revolution Medicines Stock Performance

Shares of NASDAQ RVMD opened at $207.88 on Monday. Revolution Medicines, Inc. has a 1-year low of $37.56 and a 1-year high of $224.31. The company has a market cap of $44.56 billion, a PE ratio of -23.57 and a beta of 1.39. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40. The company has a 50-day moving average of $193.33 and a two-hundred day moving average of $148.95.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same period in the previous year, the business posted ($1.31) earnings per share. As a group, equities analysts expect that Revolution Medicines, Inc. will post -8.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on RVMD. Mizuho boosted their price target on Revolution Medicines from $185.00 to $215.00 and gave the company an “outperform” rating in a research note on Monday, July 6th. Wedbush lifted their price objective on Revolution Medicines from $201.00 to $225.00 and gave the company an “outperform” rating in a report on Thursday. Wolfe Research reaffirmed an “outperform” rating and issued a $220.00 target price on shares of Revolution Medicines in a report on Monday, August 10th. Truist Financial increased their target price on shares of Revolution Medicines from $231.00 to $239.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, HC Wainwright lifted their price target on shares of Revolution Medicines from $195.00 to $280.00 and gave the company a “buy” rating in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Revolution Medicines presently has a consensus rating of “Moderate Buy” and a consensus target price of $198.89.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial opportunity. Rasonque became the first broad RAS-targeted therapy approved for metastatic pancreatic cancer and Revolution Medicines’ first marketed product. The approval arrived roughly five weeks after filing through the FDA’s national priority voucher program. In the pivotal RASolute 302 trial, the treatment reportedly nearly doubled survival outcomes, supporting expectations for rapid adoption. RVMD Secures FDA Win
• Positive Sentiment: Analysts raised their valuations. Guggenheim increased its price target to $275 from $240 with a Buy rating, while HC Wainwright maintained a Buy rating and a $280 target. Analysts cited potential peak sales of approximately $11.5 billion, and RBC viewed the planned launch as comparatively rapid. Revolution Medicines FDA Approval and Peak Sales
• Neutral Sentiment: Much of the good news may already be reflected in the stock. RVMD recently reached an all-time high above $224 and its market capitalization approached $47 billion. Commentary suggests investors had already priced in a successful approval, limiting additional upside from the announcement. Revolution Medicines Valuation Analysis
• Negative Sentiment: Profit-taking and risk concerns are weighing on shares. Despite the “transformative” approval, the stock is facing a weekly decline as investors lock in gains after a more-than-fivefold rally. Revolution Medicines remains unprofitable, with analysts forecasting negative EPS for 2027, although losses are expected to narrow to $6.86 per share for the full year. Revolution Medicines Shares Despite FDA Approval

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.